All In Biotech

Drug Trial Radar · NCT07930936

Immunotherapy and Irreversible Electroporation (IRE) in the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Immunotherapy and Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jan 1, 2030

Study completion Jan 1, 2031

Sponsor

Lead sponsor
Robert C. MartinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety, tolerability, and preliminary effectiveness of the study drug, IP-001, in patients with locally advanced pancreatic cancer that is treated with IRE.

Conditions

  • Locally Advanced Pancreatic Adenocarcinoma

Interventions

  • 1.0% IP-001 for injectionDrug

    Participants will receive intratumoral injection of 1% IP-001 (diluted to 1 mg/mL, up to 12 mL total) into and around the treated tumor and ablated area immediately following IRE

  • Irreversible ElectroporationProcedure

    Participants will undergo IRE of the tumor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of IP-001 administered intratumorally following IRETime frame: Day 0 to 90 days after treatment or the start of subsequent anti-cancer therapy, whichever comes first

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Louisville

    Louisville, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.